🫁 Most patients with #BRAF - mutant #NSCLC harbor a *non V600* alteration - a major therapeutic blind spot.

Here, we review the complex biology and therapeutic challenges for non-V600 #BRAF–driven #NSCLC

📑
authors.elsevier.com/a/1mTV35Xq2Q...

#BOLEROConsortium
@jtoonline.bsky.social